Radioligand binding evidence implicates the brain 5-HT2 receptor as a site of action for LSD and phenylisopropylamine hallucinogens
Alterations in brain serotonergic function have been implicated in the mechanism of action of LSD, mescaline, and other similarly acting hallucinogenic drugs of abuse such as STP (2,5-dimethoxyphenylisopropylamine; DOM). In order to test the hypothesis that the mechanism of action of LSD and phenyli...
Saved in:
Published in | Psychopharmacology Vol. 94; no. 2; p. 213 |
---|---|
Main Authors | , , |
Format | Journal Article |
Language | English |
Published |
Germany
01.02.1988
|
Subjects | |
Online Access | Get more information |
Cover
Loading…
Abstract | Alterations in brain serotonergic function have been implicated in the mechanism of action of LSD, mescaline, and other similarly acting hallucinogenic drugs of abuse such as STP (2,5-dimethoxyphenylisopropylamine; DOM). In order to test the hypothesis that the mechanism of action of LSD and phenylisopropylamine hallucinogens is through stimulation of a specific brain serotonin receptor sub-type, the affinities of these compounds for radiolabelled 5-HT2, 5-HT1A, 5-HT1B, and 5-HT1C receptors have been determined using recently developed in vitro radioligand binding methodologies. The 5-HT2 receptor was labelled with the agonist/hallucinogen radioligand 3H-DOB (4-bromo-2,5-dimethoxyphenylisopropylamine). The 5-HT1A, 5-HT1B, and 5-HT1C receptors were labelled with 3H-OH-DPAT, 3H-5-HT, and 3H-mesulergine, respectively. In general, the phenylisopropylamines displayed 10-100 fold higher affinities for the 5-HT2 receptor than for the 5-HT1C receptor and 100-1000 fold higher affinities for the 5-HT2 receptor than for the 5-HT1A or 5-HT1B receptor. There was a strong correlation between hallucinogenic potencies and 5-HT2 receptor affinities of the phenylisopropylamines (r = 0.90); the correlation coefficients for the 5-HT1A, 5-HT1B, and 5-HT1C were 0.73, 0.85, and 0.78, respectively. Because there is no evidence that 5-HT1A-selective or 5-HT1B-selective agonists are hallucinogenic and because the phenylisopropylamines are potent hallucinogens, a 5-HT2 receptor interaction is implicated and supports our previous suggestions to this effect. A secondary role for 5-HT1C receptors cannot be discounted at this time. |
---|---|
AbstractList | Alterations in brain serotonergic function have been implicated in the mechanism of action of LSD, mescaline, and other similarly acting hallucinogenic drugs of abuse such as STP (2,5-dimethoxyphenylisopropylamine; DOM). In order to test the hypothesis that the mechanism of action of LSD and phenylisopropylamine hallucinogens is through stimulation of a specific brain serotonin receptor sub-type, the affinities of these compounds for radiolabelled 5-HT2, 5-HT1A, 5-HT1B, and 5-HT1C receptors have been determined using recently developed in vitro radioligand binding methodologies. The 5-HT2 receptor was labelled with the agonist/hallucinogen radioligand 3H-DOB (4-bromo-2,5-dimethoxyphenylisopropylamine). The 5-HT1A, 5-HT1B, and 5-HT1C receptors were labelled with 3H-OH-DPAT, 3H-5-HT, and 3H-mesulergine, respectively. In general, the phenylisopropylamines displayed 10-100 fold higher affinities for the 5-HT2 receptor than for the 5-HT1C receptor and 100-1000 fold higher affinities for the 5-HT2 receptor than for the 5-HT1A or 5-HT1B receptor. There was a strong correlation between hallucinogenic potencies and 5-HT2 receptor affinities of the phenylisopropylamines (r = 0.90); the correlation coefficients for the 5-HT1A, 5-HT1B, and 5-HT1C were 0.73, 0.85, and 0.78, respectively. Because there is no evidence that 5-HT1A-selective or 5-HT1B-selective agonists are hallucinogenic and because the phenylisopropylamines are potent hallucinogens, a 5-HT2 receptor interaction is implicated and supports our previous suggestions to this effect. A secondary role for 5-HT1C receptors cannot be discounted at this time. |
Author | Lyon, R A Titeler, M Glennon, R A |
Author_xml | – sequence: 1 givenname: M surname: Titeler fullname: Titeler, M organization: Department of Pharmacology and Toxicology, Albany Medical College, NY 12208 – sequence: 2 givenname: R A surname: Lyon fullname: Lyon, R A – sequence: 3 givenname: R A surname: Glennon fullname: Glennon, R A |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/3127847$$D View this record in MEDLINE/PubMed |
BookMark | eNotkE1LAzEURbOo1La6cS-8PzD6kkwz06XUjwoFQeu6vEnetJGZZJhMha7941bs3Vy4HM7iTsUoxMBC3Ei8k4jFfVUjysKUeTESE0StMy3n5aWYpvSFp-RlPhZjLVVxQibi552cj43fUXBQ-eB82AF_e8fBMvi2a7ylgRMMe4aqJx9gnq02Cnq23A2xB0pAkPzAEGsgO_gYoD7t649H-JN2ew7HxqfY9bE7NtT6wLCnpjlYH-KOQ7oSFzU1ia_PPROfz0-b5Spbv728Lh_Wmc1lOWS6rrRdVIiEeeHI4KKUZBfOGu0qdro2pEypnXFKOZbsTKEtotFWFVjnczUTt__e7lC17LZd71vqj9vzGeoXM-JiMQ |
CitedBy_id | crossref_primary_10_1016_j_neuropharm_2015_08_034 crossref_primary_10_1016_S0149_7634_99_00037_8 crossref_primary_10_1007_BF00451682 crossref_primary_10_1038_s41467_023_44016_1 crossref_primary_10_1111_j_1600_0773_1989_tb00623_x crossref_primary_10_1016_j_bbagen_2009_06_009 crossref_primary_10_1038_sj_npp_1301600 crossref_primary_10_1016_0014_2999_89_90178_7 crossref_primary_10_1124_pharmrev_120_000056 crossref_primary_10_1016_S0006_8993_99_01224_X crossref_primary_10_1016_S0091_3057_96_00469_8 crossref_primary_10_1016_S0149_7634_05_80054_5 crossref_primary_10_1007_s00213_008_1247_z crossref_primary_10_3390_molecules29050964 crossref_primary_10_1016_0091_3057_92_90488_2 crossref_primary_10_1007_s00213_004_2108_z crossref_primary_10_1111_j_1476_5381_1990_tb14138_x crossref_primary_10_1046_j_1460_9568_1999_00708_x crossref_primary_10_1016_j_pharmthera_2007_06_007 crossref_primary_10_1016_S0091_3057_01_00720_1 crossref_primary_10_1021_cr078224o crossref_primary_10_1038_s41573_022_00421_7 crossref_primary_10_1007_s00204_015_1513_x crossref_primary_10_1124_mol_109_059204 crossref_primary_10_1016_j_bbrc_2013_11_104 crossref_primary_10_1016_0024_3205_91_90603_9 crossref_primary_10_1016_j_cell_2017_01_012 crossref_primary_10_1016_S0006_8993_01_02596_3 crossref_primary_10_1038_s41583_020_0367_2 crossref_primary_10_1007_s00213_006_0566_1 crossref_primary_10_1016_j_neuint_2010_01_010 crossref_primary_10_1016_j_pbb_2007_06_001 crossref_primary_10_1016_0091_3057_94_90077_9 crossref_primary_10_1016_S0278_5846_98_00031_1 crossref_primary_10_1007_BF02245187 crossref_primary_10_1523_JNEUROSCI_17_08_02785_1997 crossref_primary_10_1016_0091_3057_93_90120_I crossref_primary_10_1089_adt_2016_747 crossref_primary_10_1016_j_neuroimage_2019_06_053 crossref_primary_10_1016_0091_3057_92_90403_3 crossref_primary_10_1016_j_pbb_2005_05_011 crossref_primary_10_1016_j_euroneuro_2016_05_001 crossref_primary_10_1007_BF02244428 crossref_primary_10_1038_sj_bjp_0707473 crossref_primary_10_1111_j_1530_0277_1993_tb00785_x crossref_primary_10_1007_s00213_024_06635_4 crossref_primary_10_1007_BF00451678 crossref_primary_10_1016_0091_3057_89_90470_X crossref_primary_10_1016_S0091_3057_01_00767_5 crossref_primary_10_1038_sj_npp_1300711 crossref_primary_10_1177_026988118700100402 crossref_primary_10_1007_BF02247372 crossref_primary_10_1002_ddr_430160227 crossref_primary_10_1007_s12640_020_00297_8 crossref_primary_10_1007_BF02245809 crossref_primary_10_3928_0048_5713_19940301_09 crossref_primary_10_1016_S0361_9230_01_00646_3 crossref_primary_10_1007_s00213_011_2616_6 crossref_primary_10_1016_0040_4039_96_01807_2 crossref_primary_10_1007_s00213_005_0245_7 crossref_primary_10_1002_syn_890130205 crossref_primary_10_1016_0163_1047_91_80140_A crossref_primary_10_1002__SICI_1096_9861_19990628_409_2_187__AID_CNE2_3_0_CO_2_P crossref_primary_10_1111_j_1749_6632_1990_tb16914_x crossref_primary_10_1016_0306_3623_94_90035_3 crossref_primary_10_1016_0091_3057_90_90228_A crossref_primary_10_15436_2377_0902_17_1629 crossref_primary_10_1016_j_bcp_2007_07_018 crossref_primary_10_1021_jm9705925 crossref_primary_10_1007_BF02244609 crossref_primary_10_1016_0091_3057_91_90121_H crossref_primary_10_1016_S0006_3223_03_00236_1 crossref_primary_10_1016_0024_3205_88_90342_6 crossref_primary_10_1016_j_bbr_2014_07_016 crossref_primary_10_1021_jm970219x crossref_primary_10_1016_0091_3057_90_90047_L crossref_primary_10_3390_ijms23126713 crossref_primary_10_1016_0091_3057_92_90406_6 crossref_primary_10_1007_s00213_006_0358_7 crossref_primary_10_1016_j_neuropharm_2004_06_026 crossref_primary_10_1016_j_pharmthera_2003_11_002 crossref_primary_10_1007_BF02244617 crossref_primary_10_1016_S0091_3057_03_00159_X crossref_primary_10_1016_j_bbrc_2020_08_022 crossref_primary_10_1016_0091_3057_90_90098_3 crossref_primary_10_1016_j_patter_2023_100865 crossref_primary_10_1016_j_cell_2016_12_033 crossref_primary_10_3390_molecules28176236 crossref_primary_10_3389_fnhum_2017_00245 crossref_primary_10_1124_pr_110_003244 crossref_primary_10_1016_S0166_4328_97_02315_2 crossref_primary_10_1016_S0166_4328_03_00179_7 crossref_primary_10_1007_BF02245940 crossref_primary_10_1021_acsptsci_2c00177 crossref_primary_10_1016_0028_3908_95_00101_B crossref_primary_10_1016_0166_6851_91_90097_P crossref_primary_10_1016_S0006_3223_98_00036_5 crossref_primary_10_3390_ijms25010241 crossref_primary_10_1007_s00213_012_2891_x crossref_primary_10_1016_j_pharmthera_2011_10_007 crossref_primary_10_1016_j_bbr_2004_04_026 crossref_primary_10_1016_0028_3908_90_90151_G crossref_primary_10_1007_s00213_009_1718_x crossref_primary_10_1093_ijnp_pyy047 crossref_primary_10_1016_0014_2999_91_90675_G crossref_primary_10_1248_yakushi_128_1771 crossref_primary_10_1016_0091_3057_94_90542_8 crossref_primary_10_1007_BF00167563 crossref_primary_10_1007_BF00167564 crossref_primary_10_2139_ssrn_4072041 crossref_primary_10_1016_0014_2999_91_90106_Z crossref_primary_10_1111_j_1600_0773_1990_tb01604_x crossref_primary_10_1016_0014_2999_94_90690_4 crossref_primary_10_1002_dta_2245 crossref_primary_10_1016_S0306_4522_01_00170_1 crossref_primary_10_29328_journal_jnnd_1001078 crossref_primary_10_1016_j_neuropharm_2003_08_004 crossref_primary_10_1111_adb_12926 crossref_primary_10_1177_026988119500900107 crossref_primary_10_1016_j_biopsych_2014_11_015 crossref_primary_10_1124_jpet_118_251199 crossref_primary_10_2147_NDT_S371641 crossref_primary_10_1007_BF02245219 crossref_primary_10_1007_s00210_024_02983_2 crossref_primary_10_1016_j_jmgm_2012_06_006 crossref_primary_10_3390_metabo11040212 crossref_primary_10_1038_sj_bjp_0702751 crossref_primary_10_1016_j_pharmthera_2022_108195 crossref_primary_10_1021_jm960199j crossref_primary_10_1002_dta_3668 crossref_primary_10_1016_0163_7258_94_90051_5 crossref_primary_10_1016_j_euroneuro_2014_04_009 crossref_primary_10_1046_j_1460_9568_2003_02829_x crossref_primary_10_1016_0006_8993_90_91199_Q crossref_primary_10_1016_0006_3223_95_00200_6 crossref_primary_10_1111_j_1755_5949_2008_00059_x crossref_primary_10_1007_BF02244372 crossref_primary_10_1002_syn_21835 crossref_primary_10_1016_S0166_4328_00_00378_8 crossref_primary_10_1007_s40263_020_00752_2 crossref_primary_10_1007_s43440_023_00550_9 crossref_primary_10_1021_jm000339w crossref_primary_10_1021_ol0510522 crossref_primary_10_1007_BF02316866 crossref_primary_10_1016_S0278_5846_98_00024_4 crossref_primary_10_1016_S0040_4039_00_82391_6 crossref_primary_10_1034_j_1600_0773_2003_920504_x crossref_primary_10_14814_phy2_12003 crossref_primary_10_1021_acschemneuro_0c00129 crossref_primary_10_1002_syn_890050409 crossref_primary_10_1111_j_1360_0443_1994_tb03330_x crossref_primary_10_1073_pnas_0700436104 crossref_primary_10_1002_hlca_200390224 crossref_primary_10_1046_j_1468_2982_1993_1302075_x crossref_primary_10_1016_j_bmcl_2004_07_081 crossref_primary_10_3389_fnmol_2021_790213 crossref_primary_10_1016_S0091_3057_99_00178_1 crossref_primary_10_3389_fphar_2024_1334218 crossref_primary_10_1038_jcbfm_1995_99 crossref_primary_10_1002_ejoc_202200315 crossref_primary_10_1016_S0028_3908_99_00159_8 crossref_primary_10_3389_fnins_2020_00078 crossref_primary_10_1007_BF02253718 crossref_primary_10_1007_s00210_023_02414_8 crossref_primary_10_1016_S0091_3057_00_00241_0 crossref_primary_10_1016_S0006_2952_97_00405_X crossref_primary_10_3928_0048_5713_19930401_07 crossref_primary_10_1007_s00213_013_3303_6 crossref_primary_10_1016_j_ejphar_2019_05_014 crossref_primary_10_1016_j_neuropharm_2013_01_014 crossref_primary_10_1007_BF00441948 crossref_primary_10_1038_npp_2009_29 crossref_primary_10_1152_ajpcell_00397_2022 crossref_primary_10_1016_j_neuropharm_2011_01_012 crossref_primary_10_1016_j_bbr_2005_07_013 crossref_primary_10_1016_0361_9230_90_90194_5 crossref_primary_10_1016_j_neuropharm_2011_01_017 crossref_primary_10_1016_0091_3057_94_90172_4 crossref_primary_10_1016_S0969_8051_02_00306_2 crossref_primary_10_1016_S0149_7634_05_80158_7 crossref_primary_10_1016_0924_977X_95_00027_M crossref_primary_10_1016_0006_3223_93_90204_Q crossref_primary_10_1016_S0091_3057_01_00552_4 crossref_primary_10_7554_eLife_31991 crossref_primary_10_1016_0014_2999_96_00325_1 crossref_primary_10_1007_s40265_016_0600_5 crossref_primary_10_1016_S0306_4522_98_00043_8 crossref_primary_10_1016_j_biopha_2023_115775 crossref_primary_10_3390_molecules26092451 crossref_primary_10_1177_0269881106059583 crossref_primary_10_1016_S0091_3057_97_00527_3 crossref_primary_10_1016_S0376_8716_98_00076_3 crossref_primary_10_1177_0269881120959604 crossref_primary_10_1007_BF02246075 crossref_primary_10_1007_BF02246076 crossref_primary_10_4155_fmc_10_261 crossref_primary_10_1007_BF00168596 crossref_primary_10_1007_BF02246074 crossref_primary_10_1021_jm048963m crossref_primary_10_1021_ol034228d crossref_primary_10_1002_syn_20141 crossref_primary_10_1016_j_neuropharm_2017_07_012 crossref_primary_10_1021_acs_jmedchem_7b00085 crossref_primary_10_1093_ijnp_pyv072 crossref_primary_10_1007_BF02247721 crossref_primary_10_1021_acsptsci_2c00222 crossref_primary_10_1177_0269881105056660 crossref_primary_10_1152_physiolgenomics_00125_2003 crossref_primary_10_1111_bcp_14115 crossref_primary_10_1007_BF00442251 crossref_primary_10_1016_0014_2999_95_00279_T crossref_primary_10_3390_ijms21239279 crossref_primary_10_1016_S0169_328X_03_00029_9 crossref_primary_10_1007_s00213_004_2130_1 crossref_primary_10_1016_S0149_7634_03_00031_9 crossref_primary_10_1016_0166_4328_96_00102_7 crossref_primary_10_1016_j_euroneuro_2014_05_008 crossref_primary_10_3389_fendo_2014_00071 crossref_primary_10_1016_j_euroneuro_2022_09_004 crossref_primary_10_1517_13543784_2013_769957 crossref_primary_10_1016_S0165_0173_00_00026_6 crossref_primary_10_1007_BF02244228 crossref_primary_10_1007_BF02246643 |
ContentType | Journal Article |
DBID | CGR CUY CVF ECM EIF NPM |
DOI | 10.1007/bf00176847 |
DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) |
DatabaseTitleList | MEDLINE |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | no_fulltext_linktorsrc |
Discipline | Medicine Pharmacy, Therapeutics, & Pharmacology |
ExternalDocumentID | 3127847 |
Genre | Research Support, U.S. Gov't, P.H.S Journal Article |
GrantInformation_xml | – fundername: NIMH NIH HHS grantid: MH40716-01A2 |
GroupedDBID | -4W -BR .55 3SX 40D 40E 95. 95~ ABMNI AGWIL ALMA_UNASSIGNED_HOLDINGS CGR CUY CVF ECM EIF KOW N2Q NPM R9- RHV SBY SOJ X7M ~EX |
ID | FETCH-LOGICAL-c418t-3fb3c9b00a047da60981ac9dc63dbed3f6a2683d6d22de1ed673c0063c270f452 |
ISSN | 0033-3158 |
IngestDate | Sat Nov 02 12:12:41 EDT 2024 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 2 |
Language | English |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c418t-3fb3c9b00a047da60981ac9dc63dbed3f6a2683d6d22de1ed673c0063c270f452 |
PMID | 3127847 |
ParticipantIDs | pubmed_primary_3127847 |
PublicationCentury | 1900 |
PublicationDate | 1988-02-00 |
PublicationDateYYYYMMDD | 1988-02-01 |
PublicationDate_xml | – month: 02 year: 1988 text: 1988-02-00 |
PublicationDecade | 1980 |
PublicationPlace | Germany |
PublicationPlace_xml | – name: Germany |
PublicationTitle | Psychopharmacology |
PublicationTitleAlternate | Psychopharmacology (Berl) |
PublicationYear | 1988 |
SSID | ssj0000484 ssj0068394 |
Score | 1.7758651 |
Snippet | Alterations in brain serotonergic function have been implicated in the mechanism of action of LSD, mescaline, and other similarly acting hallucinogenic drugs... |
SourceID | pubmed |
SourceType | Index Database |
StartPage | 213 |
SubjectTerms | Amphetamines - pharmacology Animals Behavior, Animal - drug effects Brain - drug effects Brain - metabolism DOM 2,5-Dimethoxy-4-Methylamphetamine - analogs & derivatives DOM 2,5-Dimethoxy-4-Methylamphetamine - pharmacology Hallucinogens - metabolism Hallucinogens - pharmacology In Vitro Techniques Lysergic Acid Diethylamide - pharmacology Male Radioligand Assay Rats Rats, Inbred Strains Receptors, Serotonin - drug effects Receptors, Serotonin - metabolism |
Title | Radioligand binding evidence implicates the brain 5-HT2 receptor as a site of action for LSD and phenylisopropylamine hallucinogens |
URI | https://www.ncbi.nlm.nih.gov/pubmed/3127847 |
Volume | 94 |
hasFullText | |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1La9tAEF6clpZcSps29M0cSi6OirSSVtKx9GVKEkKrQG5hX2oFqS2Qc3Cu-eOd0a4lObj0cRH2LqxlfR-zs6P5Zhh7IxIZFcZSeMkoPKBoG0hb6cCiKyK01GkWkhr5-ETMzpIv5-n5ZHI1Vpcs1Vt9vVVX8j-o4hjiSirZf0C2XxQH8DPii1dEGK9_hfFXaerFZf2dgt-qdvoU69uEkv7RCdzazrlU1Atimgazkk_RytlmSemT7VRO6f1xlw6g-7zDo28fXAWBH3a-uqzbBdrZZoXkIZ-U2q9c6Xq-wPtqx86tM6bNUAy7D9eX-BNecthHeo5WXto_hFM_4xY43xw1TqGHkIR9coc3sjFJ9lxF9rWRdZ2MPZn4hsWMt1pyl7yhKtpGRe6qco4gbX52mMYRvTj98-Stmtp-ZoftZDkZxxMK8ay374SUu-6LQPfR1fH2f2lU4Ha4tV12zy9462zS-SjlQ_bAHy7gnWPKIzax8z12_9inT-yxg1OHzeoQykF31x7CAZyOUHvMbkbMAs8sWDMLBmYBMgs6ZkHHLFgzC2QLEohZsKjAMQuQWYDMAlp0G7Ngg1lP2Nmnj-X7WeDbdQQ6ifJlEFcq1lRiU4ZJZqQIizySujBaxEZZE1dCcnygRhjOjY2sEVmsyUXWPAurJOX77A5yzD5loDOT5GmlOJUOUnGhKpUqzYtQcsnxSPyM7bvnfNG4miwXHoDnv5t4wXYHrr5kdys0AfYV-pNL9brD_xeAJ3dy |
link.rule.ids | 783 |
linkProvider | National Library of Medicine |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Radioligand+binding+evidence+implicates+the+brain+5-HT2+receptor+as+a+site+of+action+for+LSD+and+phenylisopropylamine+hallucinogens&rft.jtitle=Psychopharmacology&rft.au=Titeler%2C+M&rft.au=Lyon%2C+R+A&rft.au=Glennon%2C+R+A&rft.date=1988-02-01&rft.issn=0033-3158&rft.volume=94&rft.issue=2&rft.spage=213&rft_id=info:doi/10.1007%2Fbf00176847&rft_id=info%3Apmid%2F3127847&rft_id=info%3Apmid%2F3127847&rft.externalDocID=3127847 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0033-3158&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0033-3158&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0033-3158&client=summon |